Hrt Financial LP Cara Therapeutics, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.24 - $0.92 $39,287 - $150,601	163,697 New	163,697 $42,000
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.65 $6,558 - $18,034	10,930 New	10,930 $8,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $4.94 $306,225 - $534,542	108,207 Added 166.23%	173,303 $490,000
Q1 2023 May 12, 2023	BUY	$4.89 - $12.27 $318,319 - $798,727	65,096 New	65,096 $319,000
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $428,654 - $648,523	-35,751 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.55 - $16.06 $412,924 - $574,161	35,751 New	35,751 $552,000
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $283,427 - $360,077	-22,282 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$12.34 - $17.92 $274,959 - $399,293	22,282 New	22,282 $283,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $247M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.